CPT code 87498 represents a molecular laboratory test that uses an amplified probe technique to provide a definitive diagnosis of meningitis. Nationally, accurate and timely laboratory identification of meningitis pathogens is critical for patient management, infection control, and public health reporting. Molecular amplified-probe assays offer rapid, specific detection compared with traditional culture methods, impacting treatment decisions and inpatient resource use.

Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find context on clinical utility, typical sites of service, and operational considerations tied to this diagnostic service. The summary highlights where this test fits in the diagnostic pathway for suspected meningitis and why payer coverage, coding clarity, and laboratory capabilities matter for timely diagnosis.

This publication provides benchmarks and policy-relevant discussion surrounding authorization and coverage patterns, clinical context for ordering and interpretation, and coding considerations for laboratory billing teams. Data not available in the input is noted where specific payer policy details, associated taxonomies, ICD-10 pairings, and related procedure codes are not provided.